Safety and Efficacy assessment of Monoprost® (unpreserved latanoprost) in comparison with Lumigan® 0.01 % and Lumigan® 0.03% UD, in patients with open angle glaucoma or ocular hypertension, stabilized by Lumigan® 0.01 % or Xalatan® with ocular surface intolerance. Phase IV, international, multicentre, randomised, investigator masked, 3 months duration, 3 parallel groups, 3 X 120 evaluable patients
Phase of Trial: Phase IV
Latest Information Update: 27 Jul 2017
At a glance
- Drugs Latanoprost (Primary) ; Bimatoprost
- Indications Glaucoma; Ocular hypertension
- Focus Adverse reactions
- Sponsors Laboratoires Thea
- 27 Jul 2017 This trial has been completed in Greece (end date: 28 Jul 2017).
- 18 Mar 2017 This trial has been completed in the United Kingdom (end date: 28 Jul 2016).
- 28 Oct 2016 This trial was completed in Spain, according to European Clinical Trials Database.